A key competitive advantage for AI companies lies in capturing proprietary outcomes data by owning a customer's end-to-end workflow. This data, such as which legal cases are won or lost, is not publicly available. It creates a powerful feedback loop where the AI gets smarter at predicting valuable outcomes, a moat that general models cannot replicate.

Guardant's co-CEO argues that in complex fields like diagnostics, success hinges more on innovating the business model than the core technology. Superior tech fails if it doesn't align with the unique economic incentives where the user isn't the payer.

Initially seen as a distraction, pharma partnerships became a source of high-margin, non-dilutive capital for Guardant. More importantly, buying signals from pharma served as a leading indicator for future clinical demand, de-risking their product roadmap.

As AI models become commoditized, the ultimate defensibility comes from exclusive access to a unique dataset. A startup with a slightly inferior model but a comprehensive, proprietary dataset (e.g., all legal records) will beat a superior, general-purpose model for specialized tasks, creating a powerful long-term advantage.

The vague concept of a 'data network effect' is now a real defensibility strategy in AI. The key is having a *live*, constantly updating proprietary dataset (e.g., real-time health data). This allows a commodity model to deliver superior results compared to a state-of-the-art model without access to that live data.

A new 'Tech Bio' model inverts traditional biotech by first building a novel, highly structured database designed for AI analysis. Only after this computational foundation is built do they use it to identify therapeutic targets, creating a data-first moat before any lab work begins.

The key advantage for AI biotech isn't the model itself, but generating massive, proprietary datasets ("science tokens") via automated labs. This novel data, which doesn't exist publicly, is crucial for training superior models and achieving true scientific intelligence.

Companies create defensibility by generating unique, non-public data through their operations (e.g., legal case outcomes). This proprietary data improves their own models, creating a feedback loop and a compounding advantage that large, generalist labs like OpenAI cannot replicate.

While public AI models are powerful, they risk becoming commodities when trained on the same public data. Regeneron's strategy is to create a durable advantage by training AI models on its unique dataset of millions of genomes, proteomes, and linked health records to deeply understand human biology.